Anna Tran, MD
Occupational Medicine · Glendale, AZNPI 1962523613
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 228 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,216 and has fallen 94.5% since, to $67 in 2025.
Across 228 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$717
- AstraZeneca$511
- Abbott$494
- Amgen$358
- Lilly USA, LLC$336
- Pfizer$220
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,081100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $717 |
| AstraZeneca | 27 | $511 |
| Abbott | 27 | $494 |
| Amgen | 22 | $358 |
| Lilly USA, LLC | 22 | $336 |
| Pfizer | 12 | $220 |
| Boehringer Ingelheim | 11 | $209 |
| Gilead | 8 | $168 |
| Nestle Healthcare Nutrition Inc. | 7 | $134 |
| Sanofi-aventis U.S. LLC | 6 | $101 |
| Boston Scientific | 3 | $92 |
| Astellas Pharma US Inc | 3 | $75 |
| Lucid Diagnostics Inc. | 3 | $73 |
| GSK | 4 | $71 |
| Novo Nordisk | 4 | $68 |
| Medicure Pharma Inc. | 1 | $67 |
| Amarin Pharma, Inc. | 3 | $44 |
| Bayer | 3 | $43 |
| Aimmune Therapeutics, Inc. | 2 | $36 |
| Hologic Sales And Service, LLC | 2 | $34 |
| Merck | 2 | $34 |
| Sumitomo Pharma America, Inc. | 1 | $32 |
| Nevro Corp. | 1 | $28 |
| Johnson & Johnson | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Abiomed | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Intuitive Surgical | 1 | $16 |
| Medtronic | 1 | $15 |
| Alkermes, Inc. | 1 | $15 |
| Phadia US Inc. | 1 | $12 |
How this compares
Too few occupational medicine providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 86 | $108,329 |
| JardianceEmpagliflozin | 67 | $86,787 |
| JanuviaSitagliptin Phosphate | 59 | $70,120 |
| CreonLipase/Protease/Amylase | 11 | $70,072 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $50,174 |
| EliquisApixaban | 47 | $46,980 |
| TrulicityDulaglutide | 26 | $34,462 |
| LinzessLinaclotide | 33 | $33,462 |
| ProliaDenosumab | 18 | $31,023 |
| MounjaroTirzepatide | 21 | $27,291 |
| VascepaIcosapent Ethyl | 27 | $24,845 |
| ZenpepLipase/Protease/Amylase | 13 | $22,719 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $20,398 |
| Ezetimibe | 163 | $5,914 |
| Gabapentin | 180 | $5,122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $511 | $108,32986 claims |
| AbbVieCreon, Linzess | $717 | $103,53444 claims |
| MerckJanuvia, Janumet | $34 | $90,51773 claims |
| Boehringer IngelheimJardiance | $209 | $86,78767 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $336 | $61,75247 claims |
| GSKTrelegy Ellipta | $71 | $50,17444 claims |
| PfizerEliquis | $220 | $46,98047 claims |
| AmgenProlia | $358 | $31,02318 claims |
| Aimmune Therapeutics, Inc.Zenpep | $36 | $22,71913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few occupational medicine providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other occupational medicine in Glendale
- Stefanie LundellTucson$7K
- Laura MorganTucson$425
- Ngoc ChauPhoenix$140
- Juan RodriguezScottsdale$138
- Jeffrey KiserTucson$115
- Andrew YorgasonTonopah$55
- Martti KahkonenPrescott$43
- Charles CombsTucson$34
- Christian ShawPhoenix$33
- Caryl GormanScottsdale$24
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.